# Trade Mark Journal No.2026/007 13 February 2026

## WO0000001899168 (5)

Office of origin: United States of America

Date of International Registration:22 December 2025
Date of designation in the UK: 22 December 2025

International priority date claimed: 26 June 2025 (United States of America) (99255444)

Class 5
  Pharmaceutical preparations for the treatment of endocrine and respiratory diseases and disorders, including autosomal dominant hypocalcemia type 1, hypoparathyroidism, and eosinophilic asthma.

Bridgebio Pharma, Inc.

Representative: Jessica L. Rothstein Goodwin Procter LLP, 620 Eighth Avenue, New York NY 10018, UNITED STATES OF AMERICA